Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Biological Psychiatry

• Publication date

  2006-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/J.BIOPSYCH.2005.10.021PMID 16487491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.

  2025cited by this paper
• Feature Review

  2008cited by this paper
• Metabotropic glutamate receptors

  2006cited by this paper
• Memantine for dementia.

  2006cited by this paper
• A double-blind, placebo-controlled study of memantine in the treatment of major depression.

  2006cited by this paper
• Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.

  2006cited by this paper
• Genetic or epigenetic difference causing discordance between monozygotic twins as a clue to molecular basis of mental disorders

  2005cited by this paper
• Association of valproate‐induced teratogenesis with histone deacetylase inhibition in vivo

  2005cited by this paper
• Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.

  2005cited by this paper
• Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials.

  2005cited by this paper
• Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice.

  2005cited by this paper
• Functional impairment in the remission phase of bipolar disorder.

  2005cited by this paper
• Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs

  2005cited by this paper
• Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

  2005influential reference
• Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.

  2005cited by this paper
• The increasing medical burden in bipolar disorder.

  2005cited by this paper
• Histone deacetylase inhibitors.

  2005cited by this paper
• Memantine for dementia.

  2005cited by this paper
• Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.

  2005cited by this paper
• Clinical development of histone deacetylase inhibitors as anticancer agents.

  2005cited by this paper
• Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

  2005cited by this paper
• Divalproex in the treatment of bipolar depression: a placebo-controlled study.

  2005cited by this paper
• The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis.

  2004cited by this paper
• Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

  2004cited by this paper
• Riluzole Enhances Glutamate Uptake in Rat Astrocyte Cultures

  2004cited by this paper
• Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder

  2004cited by this paper
• Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology

  2004cited by this paper
• CBP histone acetyltransferase activity is a critical component of memory consolidation.

  2004cited by this paper
• Dysregulation of the fibroblast growth factor system in major depression.

  2004cited by this paper
• Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.

  2004cited by this paper
• Protein Kinase C Overactivity Impairs Prefrontal Cortical Regulation of Working Memory

  2004cited by this paper
• Is impaired neurogenesis relevant to the affective symptoms of depression?

  2004cited by this paper
• Hippocampal volume measurement in older adults with bipolar disorder.

  2004cited by this paper
• Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.

  2004influential reference
• An open-label trial of riluzole in patients with treatment-resistant major depression.

  2004cited by this paper
• Epigenetic programming by maternal behavior

  2004cited by this paper
• Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats.

  2004cited by this paper
• Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

  2004influential reference
• Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder

  2004cited by this paper
• In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3

  2004cited by this paper
• Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus.

  2003cited by this paper
• Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.

  2003cited by this paper
• The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence.

  2003cited by this paper
• Ruboxistaurin (Eli Lilly).

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

  2003cited by this paper
• Chronic Elevation of Brain-Derived Neurotrophic Factor by Ampakines

  2003cited by this paper
• Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy

  2003cited by this paper
• MinireviewFinding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments

  2003cited by this paper
• GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

  2003cited by this paper
• Antagonists of the corticotropin releasing factor receptor.

  2003cited by this paper
• Glutamate receptor function in learning and memory.

  2003cited by this paper
• Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice.

  2003cited by this paper
• Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

  2003cited by this paper
• Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.

  2003cited by this paper
• The Mechanism of Presynaptic Long-Term Depression Mediated by Group I Metabotropic Glutamate Receptors

  2003cited by this paper
• GSK-3: tricks of the trade for a multi-tasking kinase

  2003cited by this paper
• Memantine for dementia.

  2003cited by this paper
• The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.

  2003cited by this paper
• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects.

  2003cited by this paper
• Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network.

  2003cited by this paper
• Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.

  2003cited by this paper
• Critical loss of CBP/p300 histone acetylase activity by caspase‐6 during neurodegeneration

  2003cited by this paper
• Metabotropic glutamate receptors (mGluRs) are involved in early phase of memory formation: possible role of modulation of glutamate release.

  2003cited by this paper
• The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders.

  2003cited by this paper
• Neuroprotective effects of antidepressant and mood stabilizing drugs.

  2002cited by this paper
• Label Trial of C-1073 ( Mifepristone ) for Psychotic Major Depression *

  2002cited by this paper
• Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

  2002cited by this paper
• The Wnt Signaling Pathway in Bipolar Disorder

  2002cited by this paper
• Cell pathology in bipolar disorder.

  2002cited by this paper
• Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders.

  2002cited by this paper
• Update on the therapeutic potential of PDE4 inhibitors

  2002cited by this paper
• Mood stabilizers, glycogen synthase kinase-3beta and cell survival.

  2002cited by this paper
• 77 CURRENT AND EMERGING TREATMENTS FOR ACUTE MANIA AND LONG-TERM PROPHYLAXIS FOR BIPOLAR DISORDER

  2002cited by this paper
• Neurobiology of depression.

  2002cited by this paper
• Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?

  2002cited by this paper
• Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation

  2002cited by this paper
• Antidepressants and neuroplasticity.

  2002cited by this paper
• Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.

  2002cited by this paper
• Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats.

  2002cited by this paper
• Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model.

  2002cited by this paper
• 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related

  2002cited by this paper
• Mood stabilizers, glycogen synthase kinase-3β and cell survival

  2002cited by this paper
• The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.

  2001cited by this paper
• Current perspectives on the development of non-biogenic amine-based antidepressants.

  2001cited by this paper
• Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.

  2001cited by this paper
• The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration

  2001cited by this paper
• Glutamate receptor ligands as anxiolytics.

  2001cited by this paper
• Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders.

  2001cited by this paper
• Control of synapse number by glia.

  2001cited by this paper
• Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

  2001cited by this paper
• Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.

  2001cited by this paper
• Social stress exacerbates stroke outcome by suppressing Bcl-2 expression

  2001cited by this paper
• Antidepressant-like actions of an AMPA receptor potentiator (LY392098).

  2001cited by this paper
• The next generation of PDE4 inhibitors.

  2001cited by this paper
• Glia: listening and talking to the synapse

  2001cited by this paper
• Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder.

  2001cited by this paper
• A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis

  2000cited by this paper

• Oxidative Stress and Psychiatric Symptoms in Wilson’s Disease

  2025cites this paper
• Addressing Psychiatric Symptoms in Wilson’s Disease: Translational Overlap with Bipolar Disorder and Emerging Therapeutic Strategies

  2025cites this paper
• Elucidation of molecular processes and biomarkers linked to the genetic variations driving the etiology of mood disorders

  2024cites this paper
• Psychiatric Symptoms in Wilson’s Disease—Consequence of ATP7B Gene Mutations or Just Coincidence?—Possible Causal Cascades and Molecular Pathways

  2024cites this paper
• Danshensu Interventions Mediate Rapid Antidepressant Effects by Activating the Mammalian Target of Rapamycin Signaling and Brain-Derived Neurotrophic Factor Release

  2024cites this paper
• Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology.

  2024cites this paper
• New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview

  2024cites this paper
• The Role of Glutamate Underlying Treatment-resistant Depression

  2023cites this paper
• Relationship between Urinary Metabolomic Profiles and Depressive Episode in Antarctica

  2023cites this paper
• Nerve Growth Factor in Psychiatric Disorders: A Scoping Review

  2023cites this paper
• Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder

  2023cites this paper
• Hippocampal pituitary adenylate cyclase-activating polypeptide mediates rapid antidepressant-like effects of Yueju pill.

  2023cites this paper
• The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions.

  2022cites this paper
• Intracellular signaling cascades in bipolar disorder

  2022cites this paper
• Plasma BDNF concentrations and the antidepressant effects of six ketamine infusions in unipolar and bipolar depression

  2021cites this paper
• Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study

  2021cites this paper
• NDT_A_325000 2637..2646

  2021cites this paper
• Posttranslational modifications & lithium's therapeutic effect - potential biomarkers for clinical responses in psychiatric & neurodegenerative disorders.

  2021cites this paper
• Echinacoside exhibits antidepressant-like effects through AMPAR–Akt/ERK–mTOR pathway stimulation and BDNF expression in mice

  2021cites this paper
• The Neurobiology of Bipolar Disorder.

  2021cites this paper
• Bipolar disorder

  2020cites this paper
• Ketamine in Bipolar Disorder: A Review

  2020cites this paper
• NDT_A_282208 2707..2717

  2020cites this paper
• Inflammation in Bipolar Disorder (BD): Identification of New Therapeutic Targets.

  2020cites this paper
• Intracellular Signaling Cascades in Bipolar Disorder.

  2020cites this paper
• Mitochondrial Dysfunction as a Critical Event in the Pathophysiology of Bipolar Disorder.

  2020cites this paper
• The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders

  2020influential citation
• Dual Role of Autophagy in Diseases of the Central Nervous System

  2019cites this paper
• Psychiatric disorders in multiple sclerosis

  2019cites this paper
• Sasa Quelpaertensis Nakai Induced Antidepressant-Like Effect in Ovariectomized Rats

  2019cites this paper
• Gestational stress induced differential expression of HDAC2 in male rat offspring hippocampus during development.

  2019cites this paper
• Twenty years of Lithium pharmacogenetics: A systematic review.

  2019cites this paper
• In vitro effects of antidepressants and mood-stabilizing drugs on cell energy metabolism

  2019cites this paper
• Effects of lithium and valproate on behavioral parameters and neurotrophic factor levels in an animal model of mania induced by paradoxical sleep deprivation.

  2019cites this paper
• Inflamação na Doença Bipolar: Identificação de Novos Alvos Terapêuticos

  2019cites this paper
• Effects of lithium and valproate on ERK/JNK signaling pathway in an animal model of mania induced by amphetamine

  2019cites this paper
• Assessment of glutamatergic synaptic transmission and plasticity in brain slices: relevance to bioelectronic approaches

  2019cites this paper
• The Effects of the Gsk-3 Inhıbıtor Tdzd-8 on Bıpolar-Lıke Behavıoral Phenotype Induced by Hıgh Fructose Corn Syrup Consumptıon in Adolescent Rats

  2018cites this paper
• Activity Dependent Mammalian Target of Rapamycin Pathway and Brain Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Effects of Puerarin.

  2018cites this paper
• Neuronal nitric oxide synthase and affective disorders

  2018cites this paper
• Inhibition of GSK-3β on Behavioral Changes and Oxidative Stress in an Animal Model of Mania

  2018cites this paper
• Functional Analysis of iGlur Delta-2 and other Depression Associated Proteins: Role of TRK, BDNF, CYP2B6, POLG, PICK1 for Early Detection and Treatment of Depression

  2018cites this paper
• The Relationship between the Number of Manic Episodes and Oxidative Stress Indicators in Bipolar Disorder

  2018cites this paper
• High‐fructose corn syrup consumption in adolescent rats causes bipolar‐like behavioural phenotype with hyperexcitability in hippocampal CA3‐CA1 synapses

  2018cites this paper
• Meeting Emerging Challenges and Opportunities in Psychiatry Through Computational Neuroscience

  2018cites this paper
• Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective

  2018cites this paper
• Chapter 5 – Depression

  2018cites this paper
• Urinary biomarker panel for diagnosing patients with depression and anxiety disorders

  2018cites this paper
• The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain

  2018cites this paper
• Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.

  2018cites this paper
• Neurobiology of the major psychoses: a translational perspective on brain structure and function—the FOR2107 consortium

  2018cites this paper
• 9 Neurotransmission in Mood Disorders

  2018cites this paper
• GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders

  2017cites this paper
• Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

  2017cites this paper
• Omega-3 fatty acids and mood stabilizers alter behavioral and oxidative stress parameters in animals subjected to fenproporex administration

  2017influential citation
• Agmatine enhances the antidepressant-like effect of lithium in mouse forced swimming test through NMDA pathway.

  2017cites this paper
• Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy.

  2017cites this paper
• Biological hypotheses and biomarkers of bipolar disorder

  2017cites this paper
• Lithium and Tamoxifen Modulate Behavior and Protein Kinase C Activity in the Animal Model of Mania Induced by Ouabain

  2017cites this paper
• Chapter 137 – Unipolar Major Depression

  2017cites this paper
• Disruption of Neurosynaptic Physiology and Neuron Network Dysfunction in Brain Disorders: an Environmental and Occupational Health Perspective

  2017cites this paper
• Lithium and valproate act on the GSK‐3&bgr; signaling pathway to reverse manic‐like behavior in an animal model of mania induced by ouabain

  2017cites this paper
• A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts

  2016cites this paper
• Sodium butyrate has an antimanic effect and protects the brain against oxidative stress in an animal model of mania induced by ouabain.

  2016cites this paper
• Evaluation of BDNF, Calcium Homeostasis and Cell Growth in Two Putative Disease Reporter Models of Bipolar Disorder

  2016cites this paper
• Effects of prenatal Poly I:C exposure on global histone deacetylase (HDAC) and DNA methyltransferase (DNMT) activity in the mouse brain

  2016cites this paper
• Affective Temperament Profiles in Patients with Multiple Sclerosis: Association with Mood Disorders.

  2016cites this paper
• Neuroprotective Effects of Lithium in Human Brain? Food for Thought.

  2016cites this paper
• Novel Targets for Drug Treatment in Psychiatry

  2016cites this paper
• A novel pipeline for drug discovery in neuropsychiatric disorders using high-content single-cell screening of signalling network responses ex vivo

  2016cites this paper
• Drugs related to monoamine oxidase activity.

  2016cites this paper
• Towards the Molecular Foundations of Glutamatergic-targeted Anti-depressants

  2016cites this paper
• Affective Temperament Profiles in Patients with Multiple Sclerosis: Association with Mood Disorders Multipl Skleroz Hastalarinda Afektif Mizaç Özellikleri: Duygu Durum Bozukluklariyla İlişkisi

  2015cites this paper
• Ketamine uropathy: Hong Kong experience

  2015cites this paper
• Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance.

  2015cites this paper
• The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxal sleep deprivation model of mania.

  2015cites this paper
• Effects of mood stabilizers on oxidative stress-induced cell death signaling pathways in the brains of rats subjected to the ouabain-induced animal model of mania: Mood stabilizers exert protective effects against ouabain-induced activation of the cell death pathway.

  2015cites this paper
• Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder.

  2015cites this paper
• Sex differences in glutamate receptor gene expression in major depression and suicide

  2015cites this paper
• Intracerebral Administration of BDNF Protects Rat Brain Against Oxidative Stress Induced by Ouabain in an Animal Model of Mania

  2015cites this paper
• Divergent Urinary Metabolic Phenotypes between Major Depressive Disorder and Bipolar Disorder Identified by a Combined GC-MS and NMR Spectroscopic Metabonomic Approach.

  2015cites this paper
• Mechanisms underlying the neuroprotective effect of brain reserve against late life depression

  2015cites this paper
• Specific Roles of NMDA Receptor Subunits in Mental Disorders

  2015cites this paper
• Multiple Sclerosis and Bipolar Disorders

  2015cites this paper
• Antidepressant mechanisms of deep brain stimulation for treatment resistant depression

  2015cites this paper
• Decreased Right Hippocampal Volumes and Neuroprogression Markers in Adolescents with Bipolar Disorder

  2015cites this paper
• Increased neutrophil/lymphoctye ratio in patients with bipolar disorder: a preliminary study.

  2015cites this paper
• AMPA Receptor–mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role

  2015cites this paper
• Chapter 104 – Bipolar Disorder

  2015cites this paper
• Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanisms

  2015cites this paper
• Mitochondrial complex I and III mRNA levels in bipolar disorder.

  2015cites this paper
• The antidepressant effects of ketamine and the underlying mechanisms

  2015cites this paper
• Neurodegenerative changes in depression: Excitotoxicity or a deficit of trophic factors?

  2015cites this paper
• The medial forebrain bundle as a deep brain stimulation target for treatment resistant depression: A review of published data.

  2015cites this paper
• Neurobiologic Foundations of Mood Disorders

  2015cites this paper
• Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats.

  2015cites this paper
• Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach

  2014cites this paper
• Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins

  2014cites this paper
• The emerging role of dopamine–glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment

  2014cites this paper
• Chronic Treatment with Mood-Stabilizers Attenuates Abnormal Hyperlocomotion of GluA1-Subunit Deficient Mice

  2014cites this paper